Thousand Oaks, Calif.-based Amgen Inc. completed its tender offer to purchase 52,083,333 common shares, or 7.2% of its outstanding shares, at $192 apiece.
The aggregate cost of the purchase was about $10 billion.
Amgen said the tender offer was oversubscribed, and shares will be accepted on a pro rata basis. The proration factor for the tender offer is about 96.2%.
Bank of America Merrill Lynch and Morgan Stanley acted as dealer managers for the tender offer.
